I
Ian D. Pavord
Researcher at University of Oxford
Publications - 654
Citations - 55329
Ian D. Pavord is an academic researcher from University of Oxford. The author has contributed to research in topics: Asthma & Sputum. The author has an hindex of 108, co-authored 575 publications receiving 47691 citations. Previous affiliations of Ian D. Pavord include John Radcliffe Hospital & University of Warwick.
Papers
More filters
Proceedings ArticleDOI
Application of modern molecular microbiological techniques to identify treatable chronic bacterial airway infection in severe asthma
M Jabeen,Teresa L Street,Dona Foster,D Hood,Nicholas D Sanderson,Ian D. Pavord,Paul Klenerman,Hinks Tsc. +7 more
TL;DR: H. influenzae is a clinically-relevant pathogen in severe asthma that can be identified reliably using molecular microbiological methods and ongoing analysis of a larger patient cohort will allow full characterisation of this clinical phenotype.
Journal ArticleDOI
Reduction in mild exacerbation rates and improvement in asthma status following bronchial thermoplasty
Michel Laviolette,Adalberto Sperb Rubin,Neil C. Thomson,Robert Niven,Paul A. Corris,Hans Christian Siersted,Ron Olivenstein,Ian D. Pavord,David G. McCormack,John J. H. Miller,Gerard Cox +10 more
Proceedings ArticleDOI
Association between blood eosinophil count and risk of exacerbations in patients with COPD
Marjan Kerkhof,Sarang Rastogi,Marianna Alacqua,Gokul Gopalan,Sadia Halim,Rupert Jones,Chin Kook Rhee,Marc Miravitlles,Ian D. Pavord,David Price +9 more
TL;DR: The negative binomial regression was used to estimate associations between high BEC (≥ 0.45 x 109/L) and exacerbation rate, regardless of treatment regimen or adherence.
Journal ArticleDOI
S68 Copd in the ed: eosinophils, treatment and outcomes, data from the pre-award study
TL;DR: This real-world data suggests that Peripheral blood eosinophil count levels may be a useful marker for predicting important clinical outcomes in AECOPD.
Prostaglandin D2 type 2 receptor antagonism reduces airway smooth muscle mass in asthma: mechanistic insights from in vitro and computational models
Ruth Saunders,Himanshu Kaul,Rachid Berair,Sherif Gonem,Amisha Singapuri,Amanda Sutcliffe,Chachi Latifa,Michael Biddle,Davinder Kaur,Michelle Bourne,Ian D. Pavord,Andrew J. Wardlaw,Salman Siddiqui,Bindi S. Brook,Rod Smallwood,Christopher E. Brightling +15 more
TL;DR: Fevipiprant is the first drug in a randomized placebo-controlled trial to reduce airway smooth muscle mass in asthma and represents a novel therapy to ameliorate airway remodeling in asthma.